Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbmt.2014.06.039 http://scihub22266oqcxt.onion/10.1016/j.bbmt.2014.06.039 C4194218!4194218 !25017764     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25017764 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Biol+Blood+Marrow+Transplant 2014 ; 20 (11 ): 1861-4 Nephropedia Template TP {{tp|p=25017764 |t=2014. Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation |pdf=|usr=}}{{25017764 }} gab.com Text Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation JO: Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3? [REG3?], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2R?]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days +7, +14, +21, and +30. At a median follow-up of 358 days, 17 patients had experienced aGVHD with a median time to onset at day +36. Risk of aGVHD was associated with elevated plasma ST2 concentrations at day +7 (c-statistic = .72, P = .03), day +14 (c-statistic = .74, P = .02), and day +21 (c-statistic = .75, P = .02); elevated plasma REG3? concentrations at day +14 (c-statistic = .73, P = .03), day +21 (c-statistic = .76, P = .01), and day +30 (c-statistic = .73, P = .03); and elevated elafin at day +14 (c-statistic = .71, P = .04). Plasma concentrations of TNFR1 and sIL2R? were not associated with aGVHD risk at any of the time points studied. This study identified ST2, REG3?, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort. Twit Text FOAVip Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation ????Biol Blood Marrow Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25017764 #FOAvip English Wikipedia <ref>{{Cite pmid|25017764 }}</ref> Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation #MMPMID25017764 Nelson RP Jr ; Khawaja MR ; Perkins SM ; Elmore L ; Mumaw CL ; Orschell C ; Paczesny S Biol Blood Marrow Transplant 2014[Nov]; 20 (11 ): 1861-4 PMID25017764 show ga Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3? [REG3?], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2R?]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days +7, +14, +21, and +30. At a median follow-up of 358 days, 17 patients had experienced aGVHD with a median time to onset at day +36. Risk of aGVHD was associated with elevated plasma ST2 concentrations at day +7 (c-statistic = .72, P = .03), day +14 (c-statistic = .74, P = .02), and day +21 (c-statistic = .75, P = .02); elevated plasma REG3? concentrations at day +14 (c-statistic = .73, P = .03), day +21 (c-statistic = .76, P = .01), and day +30 (c-statistic = .73, P = .03); and elevated elafin at day +14 (c-statistic = .71, P = .04). Plasma concentrations of TNFR1 and sIL2R? were not associated with aGVHD risk at any of the time points studied. This study identified ST2, REG3?, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort. |Acute Disease [MESH] |Biomarkers, Tumor/*blood [MESH] |Cyclophosphamide/administration & dosage/*adverse effects [MESH] |Disease-Free Survival [MESH] |Female [MESH] |Graft vs Host Disease/*blood/*etiology [MESH] |Hematopoietic Stem Cell Transplantation/*adverse effects/methods [MESH] |Humans [MESH] |Male [MESH] |Prognosis [MESH] |Risk Factors [MESH] |Survival Analysis [MESH] |Transplantation Conditioning/*adverse effects/methods [MESH]Prognostic biomarkers for acute graft-versus-host disease risk after (epmc).pdf DeepDyve Pubget Overpricing